MannKind Co. (NASDAQ:MNKD) Shares Bought by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in MannKind Co. (NASDAQ:MNKD) by 11.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 68,744 shares of the biopharmaceutical company’s stock after purchasing an additional 7,154 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in MannKind were worth $250,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in MNKD. China Universal Asset Management Co. Ltd. increased its holdings in MannKind by 99.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 6,892 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 3,428 shares in the last quarter. Fountainhead AM LLC purchased a new position in MannKind in the 3rd quarter valued at about $41,000. Great Valley Advisor Group Inc. acquired a new stake in MannKind in the 3rd quarter worth about $54,000. C M Bidwell & Associates Ltd. purchased a new stake in MannKind during the 3rd quarter worth approximately $106,000. Finally, Sherbrooke Park Advisers LLC acquired a new position in shares of MannKind during the third quarter valued at approximately $155,000. 49.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently commented on MNKD. Wedbush reiterated an “outperform” rating and set a $10.00 price target on shares of MannKind in a research report on Wednesday, February 28th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $6.50 target price on shares of MannKind in a research report on Friday, March 15th.

MannKind Trading Up 0.2 %

Shares of MNKD stock opened at $4.40 on Tuesday. MannKind Co. has a twelve month low of $3.17 and a twelve month high of $5.75. The stock has a market cap of $1.19 billion, a price-to-earnings ratio of -88.00 and a beta of 1.34. The company’s 50-day moving average price is $4.43 and its 200-day moving average price is $3.92.

MannKind (NASDAQ:MNKD) last posted its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.02. The firm had revenue of $58.47 million during the quarter, compared to analysts’ expectations of $52.36 million. As a group, equities research analysts predict that MannKind Co. will post 0.1 EPS for the current year.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.